ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

PROGNOSIS

Our IVDR represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our technology is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing and applying a machine learning approach. As systemic mitochondrial dysfunction has been proposed just before the appearance of cerebral abnormal protein aggregates, our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.


This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser